ArticleJournal for immunotherapy of cancer2025

Response to: Comment on "Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT)".

Gliceida M Galarza Fortuna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.